Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lexicon Pharmaceuticals
Age
18–70
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Adult male and female subjects ≥18 to ≤70 years of age
Body mass index ≥18.0 to ≤36.0 kg/m2, inclusive, at Screening
Subjects with mild, moderate, or severe hepatic impairment
Control group of matched healthy subjects
Willing and able to provide written informed consent
You may not be if
Presence of clinically significant physical, laboratory, or ECG findings that may interfere with any aspect of study conduct or interpretation of results
Existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of sotagliflozin
History of any major surgery within 6 months
History of renal disease, or significantly abnormal kidney function test
Women who are breastfeeding or are planning to become pregnant during the study
Clareo Health | PK Study of Sotagliflozin in Subjects With Hepatic Impairment
